In the phase 3 LUNA trial, atogepant demonstrated a significant reduction in migraine days during the perimenstrual period compared with placebo.

Phase 3 Emerge trial results show a single 100µg dose of lysergide ODT produced rapid, statistically significant, and durable improvements in depression scores through 12 weeks.

B-cell-depleting therapy linked to lower relapse incidence, greater T2 lesion volume reduction compared with oral platform therapies ...

HealthDay News — From 2019 to 2026, there was an increase in glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescribing for children aged 8 to 11 years without diabetes but with obesity, ...

FDA grants Fast Track designation to pacritinib for VEXAS syndrome, providing a potential therapeutic option for a severe hemato-inflammatory condition with no current approved treatments.

The FDA has granted Priority Review to the supplemental Biologics License Application for satralizumab for MOGAD, marking a potential first-in-class targeted treatment for this rare central nervous ...

Phase 2 IMPACT trial results show that adding certolizumab pegol to standard heparin and aspirin significantly lowers adverse pregnancy outcomes in high-risk antiphospholipid syndrome.

Stage 1 to 3 CKM syndrome linked to significantly higher mean-mean, mean-maximum carotid intima-medial thickness.

Smartwatches significantly overestimate how many calories people burn during exercise, according to a study published online ...

Areas under curve were 0.79, 0.78, and 0.86 for hypertension, ischemic heart disease, and cerebrovascular accident, respectively.

Phase 3 HAELO data showed an 87% reduction in monthly attack rates with Ionvoguran ziclumeran, with a PDUFA target date of March 10, 2027.

Preoperative iron is associated with an improvement in number of days alive and at home in the first 90 days after surgery.